Literature DB >> 10397695

Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo.

A Weltermann1, M Wolzt, K Petersmann, C Czerni, U Graselli, K Lechner, P A Kyrle.   

Abstract

Vascular endothelial growth factor (VEGF) is important for the proliferation, differentiation, and survival of microvascular endothelial cells. It is a potent angiogenic factor and a specific endothelial cell mitogen that increases fenestration and extravasation of plasma macromolecules. Recently, large quantities of VEGF were detected in human megakaryocytes. Incubation of human platelets with thrombin in vitro resulted in the release of large amounts of VEGF. To investigate whether VEGF is released from platelets during coagulation activation in vivo, we measured in human subjects VEGF at the site of plug formation, ie, in blood emerging from a standardized injury made to determine bleeding time (shed blood). VEGF was also determined in the same volunteers after treatment with the specific thrombin inhibitor recombinant hirudin (r-hirudin). In a double-blind, randomized, crossover study, 17 healthy male volunteers (aged 20 to 35 years) were investigated. VEGF concentrations were measured in venous blood and in shed blood by the use of an immunoassay 10 minutes after intravenous administration of r-hirudin (0.35 mg/kg of body weight) or physiological saline. Prothrombin fragment f1.2 (f1.2) and beta-thromboglobulin (beta-TG) were determined as indicators of coagulation and platelet activation, respectively. Concentrations of VEGF, f1.2, and beta-TG in shed blood 4 minutes after injury were significantly higher than in venous blood (VEGF, 55.8+/-9.2 versus <20 pg/mL, P<0.001; f1.2, 71.3+/-10.4 versus 0.78+/-0.03 nmol/L, P<0. 001; beta-TG, 2290+/-170 versus 53.2+/-14.0 ng/mL, P<0.001). Administration of r-hirudin caused a >50% inhibition of the beta-TG and f1.2 levels in shed blood. In a similar manner, much lower amounts of VEGF were detectable at the site of plug formation after r-hirudin treatment (69.0+/-9.5 versus 37.8+/-2.6 pg/mL per minute; P=0.0015). Our data indicate that substantial quantities of VEGF are released from platelets during the interaction with the injured vessel wall in vivo. This finding may be relevant with respect to wound healing and tissue repair, tumor vascularization, or arterial thrombus formation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397695     DOI: 10.1161/01.atv.19.7.1757

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  10 in total

1.  Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers.

Authors:  Jacek Treliński; Agnieszka Wierzbowska; Anna Krawczyńska; Agata Sakowicz; Tadeusz Pietrucha; Piotr Smolewski; Tadeusz Robak; Krzysztof Chojnowski
Journal:  Int J Hematol       Date:  2010-05-15       Impact factor: 2.490

2.  Early changes in local hemostasis activation following percutaneous coronary intervention in stable angina patients: a comparison between drug-eluting and bare metal stents.

Authors:  Ailiman Mahemuti; Nicolas Meneveau; Marie-France Seronde; Francois Schiele; Vincent Descotes-Genon; Fiona Ecarnot; Marie-Cecile Blonde; Mariette Mercier; Evelyne Racadot; Jean-Pierre Bassand
Journal:  J Thromb Thrombolysis       Date:  2008-09-03       Impact factor: 2.300

Review 3.  Platelet alpha-granules: basic biology and clinical correlates.

Authors:  Price Blair; Robert Flaumenhaft
Journal:  Blood Rev       Date:  2009-05-17       Impact factor: 8.250

Review 4.  A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: is the current literature meaningful?

Authors:  E Hormbrey; P Gillespie; K Turner; C Han; A Roberts; D McGrouther; A L Harris
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

5.  Systemic blood coagulation activation in acute coronary syndromes.

Authors:  Anetta Undas; Konstanty Szułdrzyński; Kathleen E Brummel-Ziedins; Wiesława Tracz; Krzysztof Zmudka; Kenneth G Mann
Journal:  Blood       Date:  2008-10-17       Impact factor: 22.113

6.  The effect of a dual or a triple antithrombotic therapy with apixaban on thrombus formation in vivo and in an ex vivo perfusion chamber model: An open-label, controlled, sequential study.

Authors:  Stefan Weisshaar; Brigitte Litschauer; Sebastian Bucher; Martin Riesenhuber; Stylianos Kapiotis; Paul Alexander Kyrle; Michael Wolzt
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 7.  Synergistic Effects of Vascular Endothelial Growth Factor on Bone Morphogenetic Proteins Induced Bone Formation In Vivo: Influencing Factors and Future Research Directions.

Authors:  Bo Li; Hai Wang; Guixing Qiu; Xinlin Su; Zhihong Wu
Journal:  Biomed Res Int       Date:  2016-12-13       Impact factor: 3.411

8.  Tamoxifen Prevents Peritendinous Adhesions: A Preliminary Report.

Authors:  Oguz Kayiran; Suphan Tunc; Guler Gamze Eren Ozcan; Neslihan Kaya; Derya Karabulut
Journal:  Biomed Res Int       Date:  2022-09-20       Impact factor: 3.246

9.  Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer.

Authors:  Yoshie Nakayama; Yoshinori Ito; Masahiko Tanabe; Shunji Takahashi
Journal:  Case Rep Oncol       Date:  2013-01-23

10.  Mild Hypoxia Enhances the Expression of HIF and VEGF and Triggers the Response to Injury in Rat Kidneys.

Authors:  Yaya Xu; Xiangmei Kong; Jiru Li; Tiantian Cui; Yifan Wei; Jiayue Xu; Yueniu Zhu; Xiaodong Zhu
Journal:  Front Physiol       Date:  2021-06-25       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.